Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.

The clinical-stage immunology company reported a quarterly loss of $0.61 per share, which beat the analyst consensus estimate of $0.71 by 13.72%. This represents a 19.74% improvement over the loss of $0.76 per share from the same period last year. Additionally, the company's net loss of $110.64 million was better than the expected $125.06 million.

Immunovant also reported a strong cash position of $994.5 million as of December 31, 2025, which provides extended runway for its drug development programs. The company recently completed a $550 million financing round, further supporting the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track with topline data expected in 2026 and 2027.